Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 253128-41-5
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of eribulin during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during eribulin therapy and for 2 weeks after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Eribulin
CAS Registry Number
253128-41-5
Drug Class
Breast Feeding
Lactation
Milk, Human
Antineoplastic Agents
Antimitotic Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Review Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.[Clin Ther. 2012]Review Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.Scarpace SL. Clin Ther. 2012 Jul; 34(7):1467-73. Epub 2012 Jun 25.
- Neuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy.[Neurotox Res. 2013]Neuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy.Wozniak KM, Wu Y, Farah MH, Littlefield BA, Nomoto K, Slusher BS. Neurotox Res. 2013 Oct; 24(3):338-44. Epub 2013 Apr 30.
- Macromolecular interaction of halichondrin B analogues eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugation.[Biochemistry. 2009]Macromolecular interaction of halichondrin B analogues eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugation.Alday PH, Correia JJ. Biochemistry. 2009 Aug 25; 48(33):7927-38.
- A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.[Clin Cancer Res. 2009]A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, Desjardins C, Fang F, Jansen M, Shuster DE, et al. Clin Cancer Res. 2009 Jun 15; 15(12):4207-12. Epub 2009 Jun 9.
- Review Eribulin: a novel cytotoxic chemotherapy agent.[Ann Pharmacother. 2012]Review Eribulin: a novel cytotoxic chemotherapy agent.Preston JN, Trivedi MV. Ann Pharmacother. 2012 Jun; 46(6):802-11. Epub 2012 May 22.
- Eribulin - Drugs and Lactation Database (LactMed®)Eribulin - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...